Non-alcoholic fatty liver disease future or investigational therapies
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease future or investigational therapies |
|
FDA on Non-alcoholic fatty liver disease future or investigational therapies |
|
CDC on Non-alcoholic fatty liver disease future or investigational therapies |
|
Non-alcoholic fatty liver disease future or investigational therapies in the news |
|
Blogs on Non-alcoholic fatty liver disease future or investigational therapies |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parth Vikram Singh, MBBS
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future investigational therapies for MASH include tirzepatide and other dual- or triple-incretin receptor agonists, gliflozins, pan-peroxisome proliferator-activated receptor agonists such as lanifibranor, fibroblast growth factor 21 analogs, fatty acid synthase inhibitors, and genetic target-based therapies such as antisense oligonucleotides targeting PNPLA3.[1]
Blood-based biomarkers of fibrosis and vibration-controlled transient elastography are expected to be used more frequently to monitor disease progression and regression, predict long-term liver-related events, and assess treatment response. Polygenic risk scores, metabolic signatures, and microbiome signatures may help identify patients with distinct MASLD trajectories and treatment responses.